As for the molecular mechanism, although Wnt/β-catenin, MYC, and Hippo pathways have been reported to be involved in the pathogenesis of hepatoblastoma 14-16, little is known about the molecular basis of this disease, and there are no validated prognostic or therapeutic biomarkers for hepatoblastoma patients. This evidence concerns the gene MYC and hepatoblastoma.